Berwyn-based Annovis Bio is delaying the release of the late-stage study results of its experimental Parkinson’s disease treatment, writes John George for the Philadelphia Business Journal.

The company planned to release phase 3 data for buntanetap in late January. This is usually the last hurdle that has to be successfully cleared by a drug developer before seeking approval for a new drug candidate.

The delay is caused by ongoing “data cleaning” efforts to ensure the study results are accurate and reliable, said Maria Maccecchini, founder and CEO of Annovis Bio.

“We understand the potential frustration with the required extension, and we want to stress that our focus is on delivering results that are trustworthy,” she added. “We are working hard to provide them very soon.”

Annovis will remain blinded to the results for the duration of the cleaning process that is being performed by an outside organization. Additionally, a statistical analysis of the study still needs to be performed.

A new target date for when the results from the late-stage clinical trial will be provided was not set by the company.

Read more about Annovis Bio and its experimental Parkinson’s disease treatment in the Philadelphia Business Journal.

______